Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Instituto de Medicina Molecular João Lobo Antunes | OTHER |
Not provided
Not provided
Not provided
Not provided
Sepsis is a life-threatening infection with increasing incidence, and its spectrum of disease can involve cardiac dysfunction, which further adds to mortality. Although cardiac involvement in sepsis has been classically attributed to systolic dysfunction, diastolic dysfunction is increasingly diagnosed due to new echocardiographic techniques and the conceptual evolution of diastolic dysfunction. Combining systolic and diastolic dysfunction assessment could lead to a better diagnosis of septic cardiac dysfunction. Furthermore, earlier forms of septic cardiac dysfunction could be more promptly recognized by measuring novel and less used parameters of diastolic dysfunction. We hypothesize that left atrium (LA) strain and isovolumetric relaxation time (IVRT) derived intervals could be new and earlier predictors of diastolic dysfunction in septic patients with a potential impact on clinical presentation and prognosis and that rare genetic variation associated with inherited cardiomyopathies could underline the risk and severity of sepsis-related myocardial dysfunction with potential impact on diagnosis and prognosis.
Primary outcome:
Presence of diastolic dysfunction at baseline or during evolution in patients presenting with septic shock and its impact on prognosis.
Secondary outcomes:
Development of heart failure symptoms and presence of myocardial dysfunction (either systolic or diastolic) at 30th day, 30-day mortality, mechanical ventilation duration, ICU length of stay, and hospital stay, and need for therapeutic change.
Mid-term prognosis will be assessed at six months follow-up for evaluation of the clinical functional class, LV systolic and diastolic function, and biomarkers.
METHODS AND TASK DESCRIPTION A prospective multicenter observational study in the 24-bed polyvalent ICU of Hospital Garcia de Orta, Almada, Portugal. Expected sample size of 140 patients, to have a confidence level of 95%, with a precision within ± 5% (population of septic patients in the ICU/yearly).
Population :
Study design summary A comprehensive echocardiogram is performed by an intensive care and echocardiography specialist at five-time points: the earliest opportunity following admission (< 24h); from 3rd to 5th day; from 7th to 10th day; 28th to 30th day or at ICU discharge, if before; and at 6-month (either in hospital or ambulatory) and at 28th day. Also, invasive arterial pressure and central venous pressure, and cardiac biomarkers (highly sensitive troponin T and NT-proBNP) will be measured in all the timepoints, and inflammatory biomarkers (adrenomedullin, IL-1 and 6) will be measured at baseline, between day 7 and 10, and at 28th day or discharge and at 6 months.
Echocardiography All echocardiographic measures are obtained with simultaneous ECG display, and the three different sets of measures are obtained with the patient in the same position. All Doppler measurements are averaged from three measurements in sinus rhythm.
In addition to the qualitative examination of chambers and valves, the following measurements are obtained via the standard parasternal and apical views:
Tissue Doppler measurements are taken from the modal velocity, from septal and lateral mitral annulus.
Systolic dysfunction is defined as those with a calculated EF < 50%. Diastolic dysfunction is classified according to 2016 ASE/EACVI guidelines with a focused analysis on the simplified criteria as E/e' >15 and e' < 0.08 m/s.
Repeated measures for different echocardiographic parameters are taken by the same physician and by two different physicians to assess inter-and intra-observer variability.
Genetic analysis For genetic analysis, blood will be withdrawn from patients at ICU admission and sent to a certified laboratory for whole-exome sequencing, in collaboration with the Institute of Molecular Medicine (IMM).
Hemodynamic monitoring Continuous hemodynamic monitoring will be achieved by a bioimpedance device - Starling Baxter - in the first 72 hours, for registration of the following variables: indexed stroke volume, stroke volume variation, cardiac output, cardiac index, heart rate, dX/dt, ventricular ejection time, total fluid content (and the dynamic variation), total peripheral resistance index and cardiac power index.
Clinical data and biochemical biomarkers All demographic, clinical, hemodynamic, respiratory data, fluid balance, vasopressors, and lab results - including highly sensitive troponin T, NT-proBNP, adrenomedullin, IL-1, and 6 - are prospectively collected, as well as SOFA, SAPS-II, APACHE-II scores, and mortality until 30 days and 6-month of follow-up.
Statistics Continuous variables are expressed as mean ± standard deviation or median and interquartile range and compared between any two groups using t-test or the Mann-Whitney U test, as appropriate. The normality of distribution is evaluated by visual inspection of histograms and by the Kolmogorov Smirnov test. Categorical variables are expressed as proportions and compared with the Mantel- Haenszel Chi-square test or Fisher exact test.
A mathematical model (curve and surface fitting, and time series regression) will be created so that the LA strain rate and IVRT variables could be predictors of early diastolic dysfunction. Associations between rare genetic variants and the development of early and late cardiac dysfunction are tested.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Echocardiography | Diagnostic Test | Echocardiography in 4 timepoints: 1st 24h + 7th-10th day; 28th-30th day; 6 months Whole exome sequencing at admission |
|
| Measure | Description | Time Frame |
|---|---|---|
| Diastolic dysfunction | Left atrium strain in % and IVRTs intervals in msec | through study completion until 6 months |
| Hereditary Cardiomyopathy genetic variants | Search for cardiomyopathies genetic variantes that could explain a myocardial susceptibility to develop injury in septic shock | through study completion until 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Heart failure | heart failure symptoms according to NYHA clarification at 30 days and 6 months | through study completion until 6 months |
| Mortality | Mortality at 30 days and 6 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
A prospective multicenter observational study in the 30-bed polyvalent ICU of Hospital Garcia de Orta, Almada, Portugal. Expected sample size of 140 patients, to have a confidence level of 95%, with a precision within ± 5% (population of septic patients in the ICU/yearly).
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Filipe A Gonzalez, MD, PhD st. | Hospital Garcia de Orta | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospital Garcia de Orta | Lisbon | Almada | 2801-267 | Portugal |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 24638143 | Background | Kaukonen KM, Bailey M, Suzuki S, Pilcher D, Bellomo R. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. JAMA. 2014 Apr 2;311(13):1308-16. doi: 10.1001/jama.2014.2637. | |
| 29846206 | Background | Walley KR. Sepsis-induced myocardial dysfunction. Curr Opin Crit Care. 2018 Aug;24(4):292-299. doi: 10.1097/MCC.0000000000000507. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D012772 | Shock, Septic |
| D009202 | Cardiomyopathies |
| ID | Term |
|---|---|
| D018805 | Sepsis |
| D007239 | Infections |
| D018746 | Systemic Inflammatory Response Syndrome |
| D007249 | Inflammation |
Not provided
Not provided
| ID | Term |
|---|---|
| D004452 | Echocardiography |
| D005820 | Genetic Testing |
| ID | Term |
|---|---|
| D057791 | Cardiac Imaging Techniques |
| D003952 | Diagnostic Imaging |
| D019937 | Diagnostic Techniques and Procedures |
| D003933 | Diagnosis |
Not provided
Not provided
Not provided
Not provided
Not provided
For genetic analysis, blood will be withdrawn from patients at ICU admission and sent to a certified laboratory for whole-exome sequencing in collaboration with the Institute of Molecular Medicine (IMM).
| through study completion until 6 months |
| 21911341 | Background | Landesberg G, Gilon D, Meroz Y, Georgieva M, Levin PD, Goodman S, Avidan A, Beeri R, Weissman C, Jaffe AS, Sprung CL. Diastolic dysfunction and mortality in severe sepsis and septic shock. Eur Heart J. 2012 Apr;33(7):895-903. doi: 10.1093/eurheartj/ehr351. Epub 2011 Sep 11. |
| 23211230 | Background | Rapezzi C, Arbustini E, Caforio AL, Charron P, Gimeno-Blanes J, Helio T, Linhart A, Mogensen J, Pinto Y, Ristic A, Seggewiss H, Sinagra G, Tavazzi L, Elliott PM. Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013 May;34(19):1448-58. doi: 10.1093/eurheartj/ehs397. Epub 2012 Dec 4. |
| 40999250 | Derived | Gonzalez FA, Bacariza J, Varudo AR, Leote J, Mateus RM, Martins CM, Ribeiro MI, Sanfilippo F, Lopes LR, Almeida AG. Sepsis-induced myocardial dysfunction diagnosed with strain versus non-strain echocardiography parameters: incidence, evolution and association with prognosis. Ann Intensive Care. 2025 Sep 25;15(1):141. doi: 10.1186/s13613-025-01561-w. |
| D010335 |
| Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D012769 | Shock |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D014463 | Ultrasonography |
| D006334 | Heart Function Tests |
| D003935 | Diagnostic Techniques, Cardiovascular |
| D019411 | Clinical Laboratory Techniques |
| D008919 | Investigative Techniques |
| D005821 | Genetic Techniques |
| D033142 | Genetic Services |
| D006296 | Health Services |
| D005159 | Health Care Facilities Workforce and Services |
| D003954 | Diagnostic Services |
| D011314 | Preventive Health Services |